Biogen Gives Up On Gosuranemab After No Benefit Seen In Alzheimer's Study
Phase II TANGO Trial Was Targeting Anti-Tau For Early Disease
Biogen’s investigational anti-tau antibody gosuranemab has missed its primary efficacy endpoint in a Phase II study in patients with Alzheimer's disease, prompting the end of the trial and termination of the compound’s further clinical development.
You may also be interested in...
Al Sandrock On His First Mission At Voyager: Cracking The Tau Alzheimer’s Puzzle
Interview: Twelve months on from exiting Biogen, Al Sandrock is once again leading innovation in neuroscience, and hopes to crack the tau nut in Alzheimer’s and prove that Voyager’s next-generation gene therapy system will be a breakthrough.
Looking Past Aduhelm, Biogen Puts Pipeline On Display
In an attempt to show Biogen has more than its troubled Alzheimer’s drug Aduhelm to drive revenue growth, the company’s R&D Day highlighted several programs from its portfolio of 33 clinical-stage assets.
AC Immune Keeps Faith In Alzheimer’s Breakthrough, But Spreads Risk With Parkinson’s Bet
Interview: The Swiss biotech has endured many Alzheimer’s failures, but has been able to broaden its portfolio and income streams while the search for a breakthrough goes on.